Scilex invests $20 million in Quantum Scan Holdings

Scilex Holding Company (NASDAQ: SCLX) announced it has made a $20 million strategic investment in Quantum Scan Holdings, Inc., a medical technology company focused on preventive diagnosis and prognosis.

The investment will support Quantum Scan's development of medical technologies including diagnostic platforms, analytics, and healthcare solutions for clinical and non-traditional care settings. Scilex stated the investment complements its existing investment in Datavault AI (NASDAQ: DVLT).

"We are grateful to Scilex for their strategic investment and confidence in our team and vision," said Mustaq Patel, Chief Executive Officer of Quantum Scan. "This capital enables Quantum Scan to accelerate its focus on forward-looking healthcare solutions and to invest in technologies that we believe can deliver long-term value and meaningful impact across the healthcare ecosystem."

Henry Ji, Chairman and Chief Executive Officer of Scilex, commented that Quantum Scan has "an experienced team with a clear focus on innovation, revenue-generation, disciplined execution, and potential large long-term value creation." He said the investment aligns with Scilex's strategic priorities and commitment to advancing healthcare solutions.

Scilex is a revenue-generating company that develops and commercializes non-opioid pain management products for acute and chronic pain treatment. The company's commercial products include ZTlido, ELYXYB, and Gloperba, all FDA-approved treatments for various pain-related conditions.

Quantum Scan Holdings is described as a medical technology and innovation company focused on developing advanced healthcare technologies, including medical platforms, diagnostics, analytics, and related innovations aimed at enhancing healthcare delivery and clinical insight.

The information is based on a press release statement from Scilex Holding Company.

You May Also Be Interested In

• FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
• Wave Life Sciences starts Phase 2a obesity trial for WVE-007 drug
• Pulsenmore partners with Ouma Health on home prenatal ultrasound